HIGHLIGHTS
- who: . et al. from the Wayne State University School of Medicine, United States have published the research work: Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review, in the Journal: (JOURNAL) of 15/04/2019
- what: For the first time, the authors report a patient with metastatic extrahepatic cholangiocarcinoma who had a durable response and good tolerance to pembrolizumab combined with nanoparticle albumin-bound (nab)-paclitaxel in a background of low tumor mutation burden (TMB), microsatellite stable (MSS), negative PD- L1 expression and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.